MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside

Table 5 MiRNAs in tumor specimens and plasma/serum samples reported to predict therapeutic response in colorectal cancer patients

miRNA	Treatment regimen	Detection method	Expression that suggests inadequate response	Patient number	Ref.
Tumor specimens
Let-7	Irinotecan, cetuximab	qRT-PCR	Low	59	[102]
miR-7	Cetuximab	qRT-PCR	Low	105	[97]
miR-21	5-FU	qRT-PCR	High	84	[90]
miR-21	5-FU	qRT-PCR	High	67	[89]
miR-21-5p	5-FU + radiation	Microarray	Low	27	[222]
miR-31-3p	Anti-EGFR	Microarray, qRT-PCR	High	33	[98]
miR-31-5p	Anti-EGFR	qRT-PCR	High	102	[100]
miR-126	Capecitabine, oxaliplatin	qRT-PCR, ISH	Low	89	[104]
miR-143	Capecitabine, oxaliplatin, anti-EGFR	Microarray, qRT-PCR	High	34	[103]
miR-146b-3p	Cetuximab	qRT-PCR	High	25	[223]
miR-148a	5-FU	qRT-PCR, ISH	Low	273	[92]
miR-150	5-FU	qRT-PCR, ISH	Low	239	[91]
miR-181a	Anti-EGFR	qRT-PCR	Low	80	[99]
miR-200 family	Fluoropyrimidine	qRT-PCR	Low	127	[103]
miR-200b	Capecitabine, oxaliplatin, anti-EGFR	Microarray, qRT-PCR	Low	34	[103]
miR-320e	5-FU, oxaliplatin	Microarray, qRT-PCR	High	100	[93]
miR-455-5p	Capecitabine, oxaliplatin, bevacizumab	qRT-PCR, ISH	High	212	[224]
miR-486-5p	Cetuximab	qRT-PCR	High	25	[223]
miR-519c	5-FU, irinotecan	qRT-PCR	Low	26	[153]
miR-592	Anti-EGFR	Microarray	Low	33	[98]
miR-625-3p	Capecitabine, oxaliplatin	Microarray, qRT-PCR	High	94	[94]
miR-664-3p	Capecitabine, oxaliplatin, bevacizumab	qRT-PCR, ISH	Low	212	[224]
Let-7c, miR-99a, miR-125b	Anti-EGFR	Microarray, qRT-PCR	Low	74	[101]
miR-1274b, miR-720	Capecitabine, oxaliplatin, radiation	Microarray, qRT-PCR	High	38	[96]
miR-107, miR-99a-3p	Fluoropyrimidine	Microarray, qRT-PCR	Low	39	[225]
miR-215, miR-190b, miR-29b-2	5-FU, radiotherapy	Microarray, qRT-PCR	High	20	[95]
Let-7e, miR-196, miR-450a, miR-450b-5p, miR-99a	5-FU, radiotherapy	Microarray, qRT-PCR	Low	20	[95]
miR-17-3p, miR-193b-5p, miR-204-5p, miR-501-5p, miR-545-3p, miR-592, miR-644-3p, miR-15a-5p, miR-196b-5p, miR-552	First-line capecitabine and oxaliplatin with or without bevacizumab	qRT-PCR, ISH	Low	212 (screening); 121 (validation)	[224]
miR-1183, miR-622. miR-765, miR-1471, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-483-5p, miR-671-5p, miR-1909	Capectabine, oxaliplatin, radiation	Microarray, qRT-PCR	Low	38	[96]
Blood
miR-19a	FOLFOXa	Microarray, qRT-PCR	High	72	[226]
miR-126	Bevacizumab		High		[104]
miR-143	Oxaliplatin	qRT-PCR	Low	62	[227]
miR-155	Leucovorin, cetuximab, 5-FU	qRT-PCR	High	15	[107]
miR-345	Cetuximab, irinotecan	Microarray, qRT-PCR	High	138	[108]
miR-1914*	Capecitabine + oxaliplatin	qRT-PCR	Low	49	[228]
miR-106a, miR-130b, miR-484	5-FU, oxaliplatin	qRT-PCR	High	150	[105]
miR-20a, miR-130, miR-145, miR-216, miR-372	FOLFOX	Microarray, qRT-PCR	High	40	[106]

FOLFOX: 5-FU + oxaliplatin + leucovorin; 5-FU: 5-fluorouracil; ISH: In situ hybridization; Anti-EGFR: Anti-EGFR targeted monoclonal antibody therapy; EGFR: Epidermal growth factor receptor.